Intrexon Corp (XON)

25.07
0.33 1.33
NYSE : Health Care
Prev Close 24.74
Open 25.00
Day Low/High 24.40 / 25.09
52 Wk Low/High 21.62 / 40.24
Volume 972.57K
Avg Volume 1.19M
Exchange NYSE
Shares Outstanding 118.58M
Market Cap 2.94B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oragenics Shareholder Update

Oragenics Shareholder Update

Oragenics, Inc. (NYSE MKT:OGEN.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Medtronic and Medicines -- have been scooping up shares of their own stock lately.

Oragenics Presents Engineering Of Improved Lantibiotic Variants At American Society For Microbiology (ASM) Conference On Antibacterial Development

Oragenics Presents Engineering Of Improved Lantibiotic Variants At American Society For Microbiology (ASM) Conference On Antibacterial Development

Oragenics (NYSE MKT:OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it presented at the American Society for...

Synthetic Biologics Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough)

Synthetic Biologics Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough)

- Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 -

Beware the Fear of Missing Out (FOMO)

Beware the Fear of Missing Out (FOMO)

There's a striking lack of volatility, and that's a flashing red warning signal.

Facebook, Apple, Starbucks: Doug Kass' Views

Facebook, Apple, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on managing and selecting short-term trades.

XON: Insiders vs. Shorts

XON: Insiders vs. Shorts

The most recent short interest data was recently released for the 11/15/2016 settlement date, and Intrexon Corp is one of the most shorted stocks of the Russell 3000, based on 12.58 "days to cover" versus the median component at 4.41. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

Oxitec Announces Friendly™ Aedes Project Is Supported By 92.8% Of Piracicaba's Population

Oxitec Announces Friendly™ Aedes Project Is Supported By 92.8% Of Piracicaba's Population

Genetically engineered mosquito that fights Aedes aegypti achieves high approval rate among residents of city where it is applied

Allergan, Macy's, Apple: Doug Kass' Views

Allergan, Macy's, Apple: Doug Kass' Views

Doug Kass shares his thoughts on closed-end municipal bond funds.

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about Friday's positives and retail's woes.

Oxitec Opens Large Scale Mosquito Production Facility In Brazil

Oxitec Opens Large Scale Mosquito Production Facility In Brazil

Capacity to Produce 60 Million Friendly™ Aedes per Week can Help Protect Up to 3 Million Brazilians from Primary Vector for Zika, Dengue and other Viruses

Lieutenant General (Ret.) Thomas P. Bostick To Lead Intrexon's Environment Sector

Lieutenant General (Ret.) Thomas P. Bostick To Lead Intrexon's Environment Sector

Former Commanding General of U.S. Army Corps of Engineers to Drive Worldwide Deployment of Oxitec's Friendly™ Mosquito

Arctic® Fuji Gains USDA Approval

Arctic® Fuji Gains USDA Approval

Intrexon To Develop Disease-Modifying Therapies In New Collaborations With Harvest Intrexon Enterprise Fund

Intrexon To Develop Disease-Modifying Therapies In New Collaborations With Harvest Intrexon Enterprise Fund

Startups to Utilize ActoBiotics™ Platform to Develop Innovative Treatments for Celiac Disease and Chronic Rhinosinusitis

'Mad Money' Lightning Round: Buy, Buy, Buy Macy's

'Mad Money' Lightning Round: Buy, Buy, Buy Macy's

Cramer favors Alibaba and Smith & Wesson.

Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering

Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering

Demand is quite healthy and markets are not going into the abyss, Cramer says.